# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Theodore Roosevelt (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI012-SYN
- Date: 2026-04-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Amos Kettering, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week asthma review after starting maintenance-and-reliever therapy. **S**

## History of present illness

Mr. Roosevelt returns four weeks after changing from albuterol alone to budesonide-formoterol two inhalations twice daily plus one as needed. He is much better: daytime symptoms on two or three days a week instead of most days, night waking once in four weeks, and he finishes his boxing rounds. He has used 4 to 6 as-needed inhalations a week, mostly before training. The dose counter matches about 90 percent of maintenance doses; he missed some evening doses on late session nights. His home peak flow ranges from 560 to 600 L/min. He has had no hoarseness or sore mouth. He still hopes training alone will eventually be enough. He saw the pulmonologist this morning. **S**

| Element | Detail |
|---|---|
| Interval change | Symptoms two or three days a week; night waking once in four weeks |
| Reliever use | 4 to 6 as-needed inhalations a week, mostly before training |
| Adherence | About 90 percent of maintenance doses by dose counter; evening doses missed on late nights |
| Home peak flow | 560 to 600 L/min |
| Medication tolerance | No hoarseness, sore mouth, or tremor |
| Patient concern | Would prefer to rely on exercise rather than medicine |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Mild wheeze on two or three days a week; no cough at night in the last three weeks |
| Ears, nose, mouth, and throat | Negative | No nasal blockage, sneezing, hoarseness, or sore mouth |
| Gastrointestinal | Negative | No heartburn or reflux |
| Psychiatric | Negative | Mood good; sleeping better |

4 systems reviewed. **S**

## Current medications

- Budesonide-formoterol 160/4.5 mcg inhaler, two inhalations twice daily for maintenance **S**
- Budesonide-formoterol 160/4.5 mcg inhaler, one inhalation as needed for symptoms and before exercise; no more than 12 inhalations a day in total **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/70 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 72.4 kg; BMI 23.6 kg/m². All vital signs are synthetic.

Asthma Control Test: 18; FeNO: 46 [ppb] (high); Blood eosinophil count: 0.42 10*3/uL; Total IgE: 260 [IU]/mL (high); Dust mite (D. pteronyssinus) specific IgE: 8.4 k[IU]/L (high). All results are synthetic.

## Change since baseline

- Asthma Control Test: 13 at baseline, 18 at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, talking easily |
| Nose | Normal mucosa; no polyps |
| Mouth | No thrush |
| Lungs | A few end-expiratory wheezes on forced expiration only |
| Inhaler technique | With his own inhaler and spacer: did not breathe out before the dose and held his breath for only two seconds; corrected, and demonstrated back correctly |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Moderate persistent asthma, improving** (J45.40). Asthma Control Test 18, up from 13 but not yet well controlled (20 or more). The pulmonology evaluation today shows type 2 inflammation (FeNO 46 ppb, blood eosinophils 0.42 x10³/µL, total IgE 260 IU/mL) with house dust mite sensitization (8.4 kU/L). Technique errors and missed evening doses explain part of the remaining symptoms. **S**
   - Continue budesonide-formoterol two inhalations twice daily and one as needed, up to 12 a day.
   - Technique corrected today; set a phone reminder for the evening dose.
   - Dust-mite-impermeable mattress and pillow covers and hot washing of bedding weekly, since sensitization is now documented.
   - One reliever inhalation 5 to 20 minutes before boxing or rowing.
   - Pneumococcal vaccine PCV20 today.
   - Repeat spirometry at the three-month review.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test | Every visit | Completed today | 18, up from 13; not yet at the target of 20 |
| Examination | Inhaler technique with his own device | Every visit | Completed today | Two critical errors corrected; correct on repeat demonstration |
| Medication safety | Adherence and reliever use | Every visit | Completed today | About 90 percent adherence; 4 to 6 as-needed inhalations a week |
| Survey | Exacerbation history | Every visit | Completed today | None since starting controller therapy |
| Self-management | Trigger and exposure review, smoking and vaping status | Every visit; detailed at diagnosis and yearly | Completed today | Colds and dust are his triggers; never smoker; no vaping; no occupational exposure |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Reviewed; peak-flow zones will be reset once his personal best is confirmed |
| Laboratory | FeNO, blood eosinophils, total IgE, and specific IgE | As indicated: diagnostic uncertainty, phenotyping, allergen-directed treatment | Completed today | Ordered by pulmonology: FeNO 46 ppb, eosinophils 0.42 x10³/µL, total IgE 260 IU/mL, dust mite IgE 8.4 kU/L |
| Referral | Pulmonology consultation | At diagnosis of uncontrolled persistent asthma | Completed today | Seen today; diagnosis confirmed and type 2 phenotype identified |
| Examination | Spirometry | At diagnosis, 3 to 6 months after stabilization, then every 1 to 2 years | Due | Baseline at intake; repeat at the three-month review |
| Examination | Home peak flow monitoring | Daily or with symptoms for moderate to severe asthma | Completed today | Readings 560 to 600 L/min; personal best still being established |
| Survey | Step-up or step-down assessment | Every visit | Completed today | Stay at Step 4; correct technique and adherence before any change |
| Examination | Comorbidity surveillance: rhinitis and sinus disease, reflux, obesity, sleep apnea, vocal cord dysfunction, anxiety and depression | At diagnosis and yearly | Completed today | None found; BMI 23.6; PHQ-2 0 at intake; no stridor or sudden throat tightness to suggest vocal cord dysfunction |
| Medication safety | Vaccination status | Yearly | Completed today | PCV20 given today; influenza vaccine this past autumn |
| Imaging | Chest radiograph or CT | Only for atypical features or suspected complication | Not indicated | Typical asthma with reversible obstruction |

## Goal progress

- Asthma Control Test score of 20 or more by the three-month review. In progress; target 2026-06-08. **S**
- FEV1 of 80 percent predicted or more on spirometry after stabilization. In progress; target 2026-06-08. **S**
- No exacerbation needing oral corticosteroids over the six months after starting controller therapy. In progress; target 2026-09-14. **S**
- Return to full boxing and rowing training without limiting symptoms. In progress; target 2026-06-08. **S**

## Guideline basis

- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026), Aether Forge

## Follow-up

- Asthma review with spirometry in two months, three months after starting controller therapy. **S**
- Next scheduled visit 2026-06-08: three-month asthma review with repeat spirometry. **S**
